Today is World Heart ❣️ Day. Started by the World Heart Federation (WHF), the theme for 2024 is “Use Heart for Action". ❤️ 💪 This non-profit urges all of us to take cardiovascular health seriously. At 23andMe, we have 3 (😮) types of genetic reports to help you understand how your DNA could impact your heart. #action Learn more about our genetic reports on heart health: https://lnkd.in/gCAYPR5D #worldheartday #awareness #cardiovascular #cardio #heart #hearthealth
About us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
- Website
-
https://www.23andme.com
External link for 23andMe
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Sunnyvale, California
- Type
- Public Company
- Specialties
- genetic research, consumer genetics, direct-to-consumer genetic testing, telehealth, healthcare, wellness, therapeutics, and drug discovery
Locations
-
Primary
223 N Mathilda Ave
Sunnyvale, California 94086, US
-
349 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at 23andMe
Updates
-
In our continued effort to work with the lung cancer community and raise awareness of our Lung Cancer Genetics Research Study, we were thrilled to participate in the GO2 for Lung Cancer annual San Francisco Bay Area 5K this past Sunday. We were inspired by the number and enthusiasm of all the attendees involved. Working with GO2 and our coalition of 20 organizations, we hope this study will provide more insight into the genetics behind lung cancer to transform our understanding of risk and treatment. Learn more here: https://lnkd.in/gmg62E7F
-
Our Therapeutics team was in Barcelona for the ESMO Congress 2024, and presented new data (including a Best Poster!) on our clinical immuno-oncology programs, 23ME-00610 and 23ME-01473. You can find more information on each program on our Therapeutics website. https://lnkd.in/gFqXnFF9
-
Anne Wojcicki was included as part of Melinda French Gates’s Vanity Fair October feature story (on stands September 17th) on women making philanthropic strides trying to improve lives around the world. French Gates notes in her interview: “I love how she talks about the example that her mom set for her—she taught Anne early on that if she didn’t like something, then she should go out and try to change it.” Read the full story: https://lnkd.in/gBa8dz_i
-
23andMe reposted this
Sickle cell trait (SCT) in itself is not a disease. It's a risk factor for venous thromboembolism (VTE), but the risk is still very small, lower than for those with heterozygous factor V Leiden (FVL), said study author Rakhi Naik. The researchers wanted to better contextualize the risk of VTE in people with SCT to help inform clinical practice guidelines and minimize unintended bias. Read more about this Blood Advances study: https://ow.ly/4SQG50Tm5Kx National Human Genome Research Institute (NHGRI) 23andMe Vence L. Bonham, Jr. J.D. #SickleCellTrait #VTE #FactorVLeiden #BloodAdvances #Genetics #HealthResearch #Thrombosis
-
1,000 participants and counting! Help us reach our goal of 10,000 participants in our Lung Cancer Genetics Study by sharing it with your friends and family. Learn more about the program here: https://lnkd.in/grZ2Pkbk
-
We are excited to announce a collaboration with California Northstate University College of Medicine to expand their pre-existing genetics program for medical students. This will involve integrating components of 23andMe’s genetic education program including videos developed by 23andMe and Osmosis.org from Elsevier covering fundamental genetics concepts to training on how to integrate genetic information into everyday patient care. Read more about this exciting collaboration: https://23and.me/4e7MMe0
23andMe Collaborates with California Northstate University to Introduce Enhanced Genetics Curriculum for Medical Students
blog.23andme.com
-
We’re looking for a Principal Product Designer to join our Design team! This is an exciting opportunity to create highly imaginative, intuitive experiences that empower individuals to gain insight into their genetic information. Come join our Gene Pool! https://lnkd.in/gNGz435v
Principal Product Designer – 23andMe Careers
23andme.com
-
On September 14 and 15 our 23andMe Therapeutics team will present new data on our two clinical immuno-oncology programs, 23ME-00610 and 23ME-01473, at the ESMO Congress 2024 in Barcelona. We’ll publish the posters on our Therapeutics and IR sites, so watch this space - and if you’re in the neighborhood, feel free to swing by! https://23and.me/3MtWFXN
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024 | 23andMe, Inc.
investors.23andme.com
-
23andMe inches closer to cancer immunotherapy, guided by its genetic database. Dr. Jennifer Low, head of 23andMe’s therapeutics division, talks about the development of oncology checkpoint inhibitors that target a unique pathway. https://lnkd.in/g5Efvfhk
23andMe inches closer to cancer immunotherapy, guided by its genetic database
pharmamore.us